Antifection

Arylomycin B2 is a potent inhibitor of signal peptidase I (SPase I), functioning as an antibiotic in the treatment of bacterial infections. It exhibits significant anti-Gram-positive bacterial activity, making it a valuable reagent for research focused on bacterial protein secretion mechanisms and antibiotic development. Arylomycin B2 can be utilized in studies assessing bacterial resistance and the efficacy of novel antibiotic therapies.

Nebramycin IV is an aminoglycoside antibiotic that primarily targets bacterial protein synthesis by binding to the 30S ribosomal subunit. It exhibits a broad spectrum of antibacterial activity, effective against both Gram-positive and Gram-negative bacteria, as well as mycobacteria. This compound is primarily utilized in research applications focused on antimicrobial resistance and the mechanisms of bacterial infections.

Pyralomicin 1a is an antibiotic that targets bacterial cell wall synthesis. It exhibits strong antibacterial activity, making it a valuable reagent for research focused on bacterial infections and resistance mechanisms. This compound can be utilized in studies investigating the efficacy of novel antibiotics and the development of therapeutic strategies against multidrug-resistant pathogens.

Isosulfazecin is a novel β-lactam antibiotic with a unique mechanism of action targeting bacterial cell wall synthesis. Isolated from Pseudomonas acidophilus sp., it demonstrates significant antimicrobial activity against both gram-positive and gram-negative bacteria, particularly against strains resistant to traditional β-lactam antibiotics. Its structure features a β-lactam ring along with methoxyl and sulfonate groups, and it is effective in research applications focusing on antibiotic resistance and the development of new antimicrobial therapies.

10-Norparvulenone is an antibiotic exhibiting activity against influenza viruses and demonstrating antibacterial effects against Escherichia coli. This compound serves as a valuable reagent for research focused on antiviral and antibacterial pathways, aiding in the exploration of treatment strategies for infections caused by these pathogens. Its dual action makes it of interest for studies investigating multi-faceted antimicrobial therapies.

Norcyclizine is a piperazine derivative that primarily targets bacterial infections through its antibiotic properties. It has been shown to enhance the antibacterial efficacy of β-lactam antibiotics, such as oxacillin, against methicillin-resistant Staphylococcus aureus (MRSA) by inhibiting the allosteric site of PBP2a. Additionally, Norcyclizine serves as a valuable pharmacological scaffold for the development of novel anticancer agents, expanding its utility in medicinal chemistry research.

Leucomycin A9 is a macrolide antibiotic that primarily targets bacterial ribosomes to inhibit protein synthesis. It exhibits strong antibacterial activity against Gram-positive bacteria and is also effective against spirochetes, Rickettsia, and Chlamydia. This compound is valuable for research applications in studying bacterial resistance mechanisms and the efficacy of antibiotic therapies.

Pyralomicin 2c is an antibiotic that exhibits potent antibacterial activity by targeting bacterial cell wall synthesis. It is effective against a range of gram-positive bacteria, making it a valuable tool for studying bacterial infections and antibiotic resistance mechanisms. This compound is suitable for research applications focused on the development of new antimicrobial agents and understanding bacterial pathogenicity.

Lomofungin is a novel antibiotic derived from Streptomyces lomondensis sp. N, exhibiting potent antibacterial properties. It primarily functions by inhibiting the binding of MBNL1 to CUG RNA, which is significant in various biological processes. This compound is valuable for research applications focused on bacterial resistance mechanisms and the regulatory roles of RNA-binding proteins.

Seldomycin factor 2 is an aminoglycoside antibiotic that targets bacterial protein synthesis. It exhibits a broad spectrum of antimicrobial activity against various Gram-positive and Gram-negative pathogens. This compound is valuable for research into antibiotic resistance mechanisms and the development of new antimicrobial therapies.

Miyakamide B2 is an antitumor antibiotic known for its insecticidal properties. It effectively inhibits the growth of Artemia salina and exhibits modest activity against Xanthomonas spp. In vitro studies demonstrate that Miyakamide B2 inhibits P388 leukemia cells, with an IC50 value of 7.6 μg/mL. This compound is valuable for research in cancer biology and antibiotic efficacy.

Decatromicin A is a potent antibiotic derived from Actinomadura MK73-NF4, exhibiting significant activity against gram-positive bacteria. Its primary mechanism involves inhibiting bacterial growth, making it a valuable tool for research into antibiotic resistance and the development of new antimicrobial strategies. Decatromicin A is particularly useful in studies focused on bacterial infections and the mechanisms of antibiotic action.

Neospiramycin I is a macrolide antibiotic that targets bacterial ribosomes, inhibiting protein synthesis. It demonstrates significant antibacterial activity against macrolide-sensitive strains of Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of 3.12 µg/mL, and exhibits effectiveness against various Gram-positive bacteria, including Bacillus cereus and Bacillus subtilis, along with Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae, at MIC values ranging from 0.2 to 50 µg/mL. In vivo, Neospiramycin I protects mice in a type III S. pneumoniae infection model, with an effective dose 50 (ED50) of 399.8 mg/kg, making it a valuable tool for studies on bacterial resistance and antibiotic efficacy.

Phenelfamycin B is an antibiotic known for its anti-eutrophic bacterial activity. This compound effectively inhibits the growth of specific bacterial strains, making it valuable in research focused on antibiotic resistance and the development of new antibacterial agents. Its unique mechanism of action positions it as a useful tool for studying bacterial inhibition in various biological assays.

4'-O-Demethyldianemycin is a polyether antibiotic isolated from Streptomyces hygroscopicus TM-531. It exhibits potent activity against Gram-positive bacteria, making it a valuable tool for studying antibiotic efficacy and resistance mechanisms in relevant microbial populations. This compound is suitable for research applications involving bacterial infections and the development of new antimicrobial agents.

Aldecalmycin is an antibiotic that exerts its effect primarily against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It demonstrates strong antimicrobial activity, with minimum inhibitory concentration (MIC) values ranging from 6.25 to 25 μg/mL. This compound is useful in research applications aimed at understanding resistance mechanisms and developing novel antibacterial strategies.

MM 42842 free acid is a monobactam antibiotic that targets bacterial cell wall synthesis. It inhibits the activity of penicillin-binding proteins, disrupting the formation of peptidoglycan in bacterial cell walls. This compound exhibits potent antibacterial activity against Gram-negative bacteria and is primarily used in research applications related to antibiotic resistance and bacterial pathogen studies.

Diolmycin A1 is an antibiotic that exhibits potent anticoccidial activity. It is primarily used in research to investigate its efficacy against coccidial infections in various animal models. This compound is of particular interest for studies focused on the treatment and prevention of coccidiosis, providing insights into its pharmacological mechanisms and potential therapeutic applications.

GSK1829820A is an antibiotic with potent antitubercular activity, specifically targeting Mycobacterium tuberculosis H37Rv. This compound exhibits inhibitory effects on the growth of the bacteria, making it a valuable tool for research focused on tuberculosis treatment and drug development. Its efficacy provides a foundation for studying mechanisms of resistance and developing new therapeutic strategies against infectious diseases.

Napsamycin A is an antibiotic that primarily exhibits antibacterial activity against Pseudomonas aeruginosa and other Pseudomonas species. Its efficacy is limited against a range of Gram-positive and other Gram-negative bacteria. This compound is valuable for research applications focused on bacterial infections and the study of antibiotic resistance mechanisms.

Dactylocycline B is an antibiotic that exhibits potent activity against gram-positive bacteria, including strains resistant to tetracycline. Its unique mode of action interferes with bacterial protein synthesis, making it a valuable tool in studying antibiotic resistance and bacterial pathogenesis. Dactylocycline B may also aid in the development of novel therapeutic strategies against challenging bacterial infections.

Inosamycin A is a broad-spectrum antibiotic that functions by inhibiting bacterial protein synthesis. It exhibits significant antibacterial activity against a variety of gram-positive and gram-negative pathogens. This compound is valuable for research applications in microbial resistance studies and the development of novel antimicrobial therapies.

Auramycin B is an anthracycline antibiotic primarily targeting Gram-positive bacteria. It demonstrates significant antibacterial activity and has also been shown to exhibit antitumor effects against P388 and L1210 leukemia cell lines in murine models. This compound is valuable for research applications focused on antibiotic efficacy and cancer therapeutics.

PKZ18 is an antibiotic that specifically targets glycyl-tRNA synthetase mRNA, inhibiting both transcription and translation in bacterial cells. It demonstrates potent antibacterial activity against Gram-positive bacteria, with minimum inhibitory concentration (MIC) values ranging from 32 to 64 μg/mL. By selectively binding to stem I specifier loops, PKZ18 effectively reduces T-box transcriptional read-through of related genes, thus disrupting the essential codon-anticodon interaction necessary for tRNA binding. This mechanism also enhances its robustness against resistance development.

Granaticin methyl ester is a quinone antibiotic targeting bacterial cell viability. This compound exhibits significant antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a valuable tool in microbiological research. Its efficacy in combating bacterial infections highlights its potential for further exploration in therapeutic applications.

Avidinorubicin is an antibiotic derived from Streptomyces avidinii, demonstrating efficacy against a range of Gram-positive and Gram-negative bacterial strains. In addition to its antibacterial properties, Avidinorubicin has been shown to inhibit thrombin-induced platelet aggregation, exhibiting an IC50 of 7.9 μM. This compound is suitable for research applications focused on antibiotic development and the study of platelet biology.

Lateropyrone is a pyranone antibiotic that primarily targets Gram-negative bacteria, exhibiting significant antimicrobial activity. It is a secondary metabolite synthesized by the oat fungal pathogen, demonstrating potential for use in pharmaceutical research to explore antibiotic resistance mechanisms and develop new antibacterial agents. Its unique structure and biological activity make it a valuable compound in studies focused on microbial interactions and pathogen inhibition.

Thiotropocin is a tropothione antibiotic that exhibits antibacterial activity against a range of Gram-positive and Gram-negative bacteria, as well as some phytopathogens and mycoplasma. It induces morphological changes in Proteus mirabilis and Escherichia coli, making it a valuable tool for studying bacterial behavior and resistance mechanisms. This compound is applicable in research focused on antibiotic efficacy and bacterial pathogenesis.

Pyloricidin C is an antibiotic targeting Helicobacter pylori, originally isolated from Bacillus sp. HC-70. This compound exhibits potent antibacterial activity, making it a valuable tool for research focused on H. pylori-related infections and resistance mechanisms. Its unique mode of action contributes to its potential applications in the development of novel antimicrobial therapies.

Pyrromycin is an antibiotic that specifically targets Gram-positive bacteria by inhibiting protein synthesis. It demonstrates potent antibacterial activity, making it suitable for research applications in microbiology and pharmacology. This compound is valuable for studying bacterial resistance mechanisms and evaluating potential therapeutic options against Gram-positive infections.

Pyralomicin 2b is an antibiotic that exerts its antimicrobial effects by inhibiting bacterial growth. It demonstrates significant antibacterial activity against various Gram-positive and Gram-negative bacteria, making it a valuable tool in research related to infectious diseases and antibiotic resistance. Its mechanism of action can be explored further in pharmacological studies and drug development efforts.

Sakyomicin C is a benzoquinone antibiotic that targets bacterial cell function. It exhibits potent activity against Gram-positive bacteria and mycobacteria, making it a valuable reagent for research in antimicrobial resistance and the development of new antibiotic therapies. Its unique mechanism of action and broad-spectrum efficacy support its use in studies focused on bacterial pathogenesis and treatment approaches.

Bottromycin A2 is a natural antibiotic that inhibits bacterial protein synthesis by targeting the ribosomal machinery. It demonstrates significant activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). This compound is valuable for research applications focused on combating antibiotic resistance and understanding the mechanisms of action in bacterial infections.

CGP 31608 is a semisynthetic penem derivative that exhibits potent antibacterial activity. Its structural modifications confer resistance to various significant beta-lactamases, including mutationally derepressed chromosomal enzymes. CGP 31608 is suitable for research applications focused on bacterial infections and the mechanisms of antibiotic resistance.

Plicacetin is a crystalline antibiotic derived from the fermentation broth of Streptomyces actinomycetes. It exhibits antibacterial properties through its ability to inhibit protein synthesis, making it relevant for research in antimicrobial resistance and therapeutic development. Its structural similarity to other antibiotics, such as Amicetin, positions it as a valuable compound for further exploration of antibiotic mechanisms and efficacy in bacterial infections.

Dechloromycorrhizin A is an antibiotic that primarily targets bacteria and has demonstrated weak activity against Gram-positive bacteria, yeasts, and mildew. Additionally, it exhibits potent nematocidal activity, making it useful in research applications focused on plant diseases and nematode management. Its unique properties render it a valuable reagent for studies in microbiology and plant pathology.

Kasugamycin sulfate is an aminoglycoside antibiotic that targets the 30S and 70S ribosomal subunits, specifically inhibiting canonical translation initiation. By mimicking mRNA nucleotides, it disrupts tRNA binding, exerting effective anti-infective activity. Additionally, kasugamycin sulfate enhances the sensitivity of mycobacteria to rifampicin in vitro and in various mouse infection models, making it a valuable tool in microbial resistance research and antibiotic development studies.

Mureidomycin E is an antibiotic that targets bacterial cell wall synthesis. It exhibits potent activity against Pseudomonas aeruginosa, a common pathogen associated with various infections. This compound is valuable in research applications focused on developing new antibacterial agents and studying mechanisms of antibiotic resistance.

Leucomycin A8 is an antibiotic derived from Streptomyces kitasatoensis, exhibiting significant antibacterial activity against a range of Gram-positive bacteria. This compound is primarily employed in infection research, contributing to studies on antimicrobial resistance and the development of new therapeutic agents. Its unique mechanism of action makes it a valuable tool for exploring bacterial protein synthesis inhibition.

DA 1131 is an anionic Carbapenem antibiotic that exhibits a broad spectrum of antibacterial activity against both gram-positive and gram-negative organisms. Its unique structure renders DA 1131 resistant to degradation by various types of β-lactamases, making it a valuable tool in the study of antibiotic resistance and the treatment of bacterial infections. This compound is particularly useful in pharmacological research aimed at developing effective therapies against resistant bacterial strains.

Antibacterial Agent 128 is an innovative siderophore analog-Ciprofloxacin conjugate featuring a cleavable linker. This compound exhibits potent antibacterial activity against Pseudomonas aeruginosa, with minimum inhibitory concentration (MIC) values ranging from 0.25 to 64 μg/mL, and against Burkholderia pseudomallei, with MIC values between 1 and 32 μg/mL. Antibacterial Agent 128 is suitable for research applications focused on combating bacterial infections and studying antibiotic resistance mechanisms.

Cefetamet sodium is a cephalosporin antibiotic that acts primarily by binding to bacterial penicillin-binding proteins (PBPs), disrupting cell wall synthesis. This compound exhibits substantial antibacterial activity against both Gram-negative bacteria, including Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, and Gram-positive bacteria such as Streptococcus. Additionally, Cefetamet sodium is effective in lysing Treponema pallidum. It is utilized in research focused on infections of the respiratory tract, urinary tract, and ear, nose, and throat, as well as in studies related to syphilis.

Mycinamicin III is an ester peptide antibiotic that demonstrates activity against Gram-positive bacteria. Its mechanism of action involves inhibiting protein synthesis, making it valuable for research applications in studying bacterial resistance and antibiotic efficacy. Mycinamicin III is useful in the development of new antibacterial agents and for investigating microbial interactions.

Lactaroviolin is an aromatic derivative antibiotic that primarily targets bacterial cell growth. It exhibits inhibitory activity against Mycobacterium tuberculosis, although its efficacy may be modest. This compound serves as a valuable tool for research in the development of novel antimicrobial strategies and understanding antibiotic resistance mechanisms in mycobacterial species.

Pneumocandin A3 is a lipopeptide antibiotic that primarily targets fungal cell wall biosynthesis. It exhibits potent anti-Candida activity, effectively inhibiting 1,3-β-glucan synthesis in vitro, with an IC50 range of 0.07-0.5 μg/mL. This compound is vital for research applications focused on antifungal drug development and the investigation of fungal resistance mechanisms.

Spectinomycin sulfate is an aminocyclitol aminoglycoside antibiotic that targets bacterial protein synthesis, derived from Streptomyces spectabilis. It exhibits bacteriostatic activity, making it effective against various bacterial infections. This compound is primarily utilized in microbiological research and clinical applications to study antibiotic resistance and the mechanisms of bacterial cell growth inhibition.

SCH 34343 is a penem antibiotic that demonstrates potent antibacterial activity against Streptococcus pneumoniae, with a minimum inhibitory concentration (MIC50) of ≤ 0.015 mg/L. It exhibits similar efficacy against viridans streptococci and multiple groups of streptococci, including A, B, C, and G, with MIC50 values ranging from 0.03 to 0.06 mg/L. This compound is suitable for antibacterial research, providing valuable insights into antibiotic efficacy and resistance mechanisms.

Pluraflavin A is an antitumor antibiotic that primarily functions by inhibiting the transcription of the glucose-6-phosphatase gene. This compound exhibits significant anti-proliferative activity against tumor cells, making it a valuable tool for cancer research. Its mechanism of action positions it as a candidate for studies focused on tumor biology and potential therapeutic interventions.

Guamecycline is a semisynthetic tetracycline that targets bacterial ribosomes to inhibit protein synthesis. It exhibits a broad spectrum of antibacterial activity comparable to that of tetracycline. This compound is utilized in research applications involving microbial resistance studies, particularly in understanding the mechanisms of antibiotic efficacy and in developing novel antimicrobial therapies.

KKL-40 is a small molecule inhibitor that targets the trans-transcription process in bacteria. It exhibits effective antibacterial activity against methicillin-sensitive and -resistant Staphylococcus aureus, as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 demonstrates a synergistic effect with the human antimicrobial peptide LL-37 against S. aureus, while showing no synergy with commonly used antibiotics such as daptomycin, kanamycin, or erythromycin. Notably, KKL-40 selectively inhibits trans-transcription without toxicity to HeLa cells, making it a valuable tool for research in bacterial genetics and antibiotic resistance.